Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-19
2011-04-19
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S017900
Reexamination Certificate
active
07928077
ABSTRACT:
The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1:or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.
REFERENCES:
patent: 5290551 (1994-03-01), Berd
patent: 6344354 (2002-02-01), Webster et al.
patent: 2007/0238871 (2007-10-01), Tsuji et al.
patent: 2008/0260774 (2008-10-01), Wong et al.
patent: 2009/0117089 (2009-05-01), Steinman et al.
patent: 2009/0233875 (2009-09-01), Tsuji et al.
patent: 2006/071848 (2006-06-01), None
patent: 2007/035717 (2007-03-01), None
patent: 2008/128207 (2008-10-01), None
Lin K-H et al. In vivo protection of bacterial and viral infections in murine models using a synthetic new α-GalCer analog, Antimicrobial Agents and Chemotherapy, 54(10):4129-36, (2010).
Li, X et al., Design of a Potent CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant, Proc. Nat. Acad. Sci. U.S.A., 107(29):13010-5, (2010).
Li, X et al., Identification of C-glycoside nalogues that display a potent biological activity against murine and human invariant atural killer T cells, Immunology 127:216-225. (2009).
Schiefner, A et al., Structural Evaluation of potent NKT Cell Agonists: Implications for Design of Novel Stimulatory Ligands, J Mol Biol 394:71-82. (2009).
Wu D., et al. Glycolipids as Immunostimulating agents, Bioorg Med Chem 16:1073-83. (2008).
Trappeniers M., et al. Synthesis and in vitro evaluation of alpha-GalCer epimers, Chem Med Chem 3:1061-70. (2008).
Kinjo Y., et al. Natural Sphingomonas Glycolipids Vary Greatly in their Ability to Activate Natural Killer T Cells, Chem. Biol., 15(7):654-664, (2008).
Liang, P-H., et al. Quantitative microarray analysis of intact lycolipid-CD1d interaction and correlation with cell-based cytokine roduction, J Am Chem Soc 130:12348-54. (2008).
Huang Y., et al., Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide, Vaccine 26:1807-1816. (2008).
Chang Y-J., et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A 104:10299-304. (2007.
Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands, Cell Mol Life Sci 63:1889-1898. (2006).
Fujio M., et al. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity, J Am Chem Soc 128:9022-3. (2006).
Wu D., et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d, Proc Natl Acad Sci U S A 103:3972-7. (2006).
Kinjo Y., et al. Recognition of bacterial glycosphingolipids by natural killer T cells, Nature 434:520-5. (2005).
Wu D., et al. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells, Proc. Natl. Acad. Sci. U.S.A., 102:1351-1356 (2005).
Fan G-T et al. Synthesis of α-galactosyl ceramide and the related glycolipids for evaluation of their activities on mouse splenocytes, Tetrahedron 61:1855-1862. (2005).
Plettenburg O., et al. Rapid preparation of glycolipid libraries by cross metathesis, Adv. Synth. Catal. 344,622-626 (2002).
Gonzalez-Aseguinolaza G., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines, J Exp Med 195:617-24. (2002).
Plettenburg O., et al. Synthesis of α-galactosyl ceramide, a potent immunostimulatory agent, J. Org Chem. 67, 4559-4564 (2002).
Chang Ya-Jen
Hung Jung-Tung
Lin Kun-Hsien
Wong Chi-Huey
Yu Alice
Academia Sinica
Eckman Basu LLP
Olson Eric S
LandOfFree
Alpha-galactosyl ceramide analogs and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-galactosyl ceramide analogs and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-galactosyl ceramide analogs and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626879